1Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [ J ]. N Engl J Med, 2007, 356:115-124.
2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [ J]. N Engl J Med, 2007, 356: 125-134.
3Hammers HI, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study[J]. Mol Cancer Ther, 2010, 9:1525-1535.
4Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance[ J]. Clin Cancer Res, 2010, 16 : 1348-1354.
5Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors [ J ]. Eur Urol, 2011, 60 : 1163-1170.
7Makhov PB, Golovine K, Kuitikov A, et al. Modulation of Akt./ mTOR signaling overcomes sunitinib resistance in renal and prostate cancer ceils [ J]. Mol Cancer Ther, 2012, 11 : 1510- 1517.
8Di Lorenzo G, Buonerba C, Fedefico P, et al. Third-line sorafenih after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma[ J]. Eur Urol, 2010, 58:906-911.
9Blesius A, Beuselinck B, Chevreau C, et al. Are tyrosine kinase inhibitors still active in patients treated with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitors and everolimus? Experience from 36 patients treated in France in the RECORD-1 Trial[ J]. Clin Genitourin Cancer, 2013, 11 : 128- 133.
10Granwald V, Seidel C, Fenner M, et al. Treatment of everolimus- resistant metastatic renal cell carcinoma with VEGF-targeted therapies[ J 1. Br J Cancer,2011, 105 : 1635-1639.
